AR039388A1 - Formulaciones liquidas de baja dosis de entecavir y uso - Google Patents

Formulaciones liquidas de baja dosis de entecavir y uso

Info

Publication number
AR039388A1
AR039388A1 ARP030101211A ARP030101211A AR039388A1 AR 039388 A1 AR039388 A1 AR 039388A1 AR P030101211 A ARP030101211 A AR P030101211A AR P030101211 A ARP030101211 A AR P030101211A AR 039388 A1 AR039388 A1 AR 039388A1
Authority
AR
Argentina
Prior art keywords
entecavir
composition
low
liquid
formulated
Prior art date
Application number
ARP030101211A
Other languages
English (en)
Inventor
Divyakant Desai
Danping Li
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR039388A1 publication Critical patent/AR039388A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Se proporcionan composiciones farmacéuticas líquidas, que tienen una baja dosis de entecavir. En una modalidad de la composición líquida de entecavir es una composición lista para usar que está formulada para ser a la vez estable y de sabor agradable. En una segunda modalidad la composición líquida de entecavir está formulada de una composición en polvo en el momento de uso. Las composiciones de baja dosis de entecavir pueden también incluir por lo menos un componente seleccionado de edulcorante, conservador, agente saborizante, agente de solución amortiguador, o combinaciones de éstos. Las composiciones líquidas de entecavir pueden también ser formuladas en combinación con otros agentes farmacéuticamente activos. Reivindicación 1: Una composición farmacéutica líquida para tratar infecciones por el virus de hepatitis B, que comprende un solvente farmacéuticamente aceptable y alrededor de 0,001% hasta alrededor de 20% p/v de entecavir.
ARP030101211A 2002-04-08 2003-04-07 Formulaciones liquidas de baja dosis de entecavir y uso AR039388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37067402P 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
AR039388A1 true AR039388A1 (es) 2005-02-16

Family

ID=29250568

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101211A AR039388A1 (es) 2002-04-08 2003-04-07 Formulaciones liquidas de baja dosis de entecavir y uso

Country Status (22)

Country Link
US (1) US20030190334A1 (es)
EP (1) EP1492510A4 (es)
JP (1) JP2005528389A (es)
KR (1) KR20040099403A (es)
CN (1) CN1319517C (es)
AR (1) AR039388A1 (es)
AU (1) AU2003226259A1 (es)
BR (1) BR0309057A (es)
CA (1) CA2481092A1 (es)
EA (1) EA008102B1 (es)
EC (1) ECSP045349A (es)
HR (1) HRP20040893A2 (es)
MX (1) MXPA04009735A (es)
MY (1) MY131488A (es)
NO (1) NO20044451L (es)
NZ (1) NZ535535A (es)
PE (1) PE20040324A1 (es)
PL (1) PL372322A1 (es)
RS (1) RS88404A (es)
TW (1) TWI275392B (es)
WO (1) WO2003086367A1 (es)
ZA (1) ZA200407672B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN1732944B (zh) * 2005-09-02 2013-05-08 海南中和药业有限公司 恩替卡韦分散片及其制备方法
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
CN101869569A (zh) * 2009-04-21 2010-10-27 李迪 即用型恩替卡韦组合物
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
SG2014011548A (en) 2011-08-16 2014-09-26 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
CN102908312B (zh) * 2011-11-10 2014-06-04 陈小花 抗乙肝病毒液体组合物
US8517850B1 (en) * 2012-12-11 2013-08-27 Cobra Golf Incorporated Golf club grip with device housing
KR101462018B1 (ko) * 2013-04-01 2014-11-19 썬시스템즈(주) 엔테카비르 함유 구강 붕해형 필름제제
CN103301071A (zh) * 2013-06-03 2013-09-18 北京阜康仁生物制药科技有限公司 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法
BR112016002342A8 (pt) * 2013-08-06 2018-01-23 Dong Kook Pharm Co Ltd microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
KR102435064B1 (ko) * 2014-06-20 2022-08-22 주식회사 씨티씨바이오 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법
CN104083374A (zh) * 2014-07-18 2014-10-08 石家庄创建医药科技有限公司 一种恩替卡韦口服液组合物
CN109984996B (zh) * 2018-01-02 2022-01-18 扬子江药业集团有限公司 恩替卡韦口服溶液及其制备方法
CN108434096A (zh) * 2018-06-20 2018-08-24 广州大光制药有限公司 一种恩替卡韦口服溶液及其制备方法
CN112334151A (zh) * 2018-06-29 2021-02-05 学校法人同志社 包含恩利卡生的制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
PL349347A1 (en) * 1999-01-12 2002-07-15 Smithkline Beecham Biolog Novel treatment
EA006181B1 (ru) * 2000-02-29 2005-10-27 Бристоль-Мейерз Сквибб Компани Фармацевтический препарат на основе энтекавира и способ его получения
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
CN1658844A (zh) 2005-08-24
NZ535535A (en) 2006-09-29
ZA200407672B (en) 2005-10-12
EP1492510A4 (en) 2006-01-11
CA2481092A1 (en) 2003-10-23
EA008102B1 (ru) 2007-04-27
HRP20040893A2 (en) 2005-02-28
MXPA04009735A (es) 2005-01-11
RS88404A (en) 2006-12-15
KR20040099403A (ko) 2004-11-26
JP2005528389A (ja) 2005-09-22
TW200306840A (en) 2003-12-01
US20030190334A1 (en) 2003-10-09
EP1492510A1 (en) 2005-01-05
BR0309057A (pt) 2005-02-01
NO20044451L (no) 2004-11-04
EA200401298A1 (ru) 2005-02-24
PE20040324A1 (es) 2004-05-29
AU2003226259A1 (en) 2003-10-27
MY131488A (en) 2007-08-30
CN1319517C (zh) 2007-06-06
ECSP045349A (es) 2005-01-03
TWI275392B (en) 2007-03-11
WO2003086367A1 (en) 2003-10-23
PL372322A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
AR039388A1 (es) Formulaciones liquidas de baja dosis de entecavir y uso
ATE294571T1 (de) Echinocandin pharmazeutische zusammensetzungen
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
CY1112523T1 (el) Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
WO2002078627A3 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
PL373276A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
HUP0301506A2 (hu) Gyógyászati készítmények nedves hámfelületek fájdalmas, gyulladásos vagy fekélyes állapotai, így például nyálkahártyagyulladás, szájgyulladás és behcet-tünetcsoport kezelésére
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
DE50109650D1 (de) Topische behandlung bei der mastalgie
BR0306923A (pt) Composição farmacêutica para regeneração de tecidos hepáticos para tratamento de cirrose do fìgado uso de 5-(2-pirazinil) -4-metil-1,2-ditiol-3-tiona
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
AR042598A1 (es) Composiciones de acetaminofeno
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica
HUP0500642A2 (hu) Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra
TR200302027T4 (tr) Hayvanlarda görülen parazit kaynaklı hastalıkarın tedavisine yönelik ilaç kompozisyonları
BR0108732A (pt) Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática
DE60031385D1 (de) Pharmazeutische Zusammensetzungen von Antibiotika und Fruktan-Gemische

Legal Events

Date Code Title Description
FA Abandonment or withdrawal